Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06011408 · ClinicalTrials.gov registry record · NA
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
A NA study of Tardive Dyskinesia, sponsored by iRxReminder.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 2
- Study locations
NCT06011408 is a NA study of Tardive Dyskinesia that is actively recruiting participants, run by iRxReminder. The registered enrollment target is 300 participants, above the 89-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (237% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06011408, a NA study of Tardive Dyskinesia, is actively recruiting participants, sponsored by iRxReminder.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
Conditions Studied
Interventions
- OTHER TDtect
Study Locations (2)
New York
- Fermata Helath - Brooklyn
Ohio
- Charak Research Center - Garfield Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06011408
The ClinicalTrials.gov registry entry for NCT06011408 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (237% higher). The listed sponsor is iRxReminder, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tardive Dyskinesia appearing as the primary indexed condition, and to 1 intervention - of which TDtect is the first listed.
NCT06011408 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06011408 about?
NCT06011408 is a clinical study titled "Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes". The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
What is the current status of trial NCT06011408?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-05-30. Estimated completion is 2024-12-31.
What conditions does trial NCT06011408 study?
This clinical trial studies the following conditions: Tardive Dyskinesia.
What interventions are being tested in trial NCT06011408?
The interventions under investigation include: TDtect (OTHER).
Who is sponsoring clinical trial NCT06011408?
This trial is sponsored by iRxReminder, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06011408 being conducted?
This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tardive Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Levetiracetam Treatment of Tardive Dyskinesia
COMPLETED · Phase 3
-
Addressing Involuntary Movements in Tardive Dyskinesia
COMPLETED · Phase 3
-
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.